EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study

Laurent Mandelbrot iD, Roland Tubiana, Pierre Frange iD, Gilles Peytavin iD, Jerome Le Chenadec, Ana Canestri, Philippe Morlat, Cécile Brunet-Cartier, Jeanne Sibiude, Delphine Peretti, Véronique Chambrin, Amélie Chabrol und 8 weitere

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad161 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Laurent Mandelbrot und 19 weiteren Autor:innen. Beteiligte Einrichtung: Assistance Publique-Hôpitaux de Paris Hôpital Louis Mourier Service de Gynécologie-Obstétrique, F-92700 Colombes, France. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: French national agency, Emerging infectious diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Because NRTIs can have fetal toxicities, we evaluated a perinatal NRTI-sparing strategy to prevent perinatal HIV transmission. Our primary objective was to determine the proportion maintaining a viral load (VL) of <50 copies/mL up to delivery on darunavir/ritonavir monotherapy, without requiring treatment intensification.

Methods

In a one-arm, multicentre Phase 2 clinical trial, eligible patients in the first trimester of pregnancy on ART with plasma VL < 50 copies/mL received maintenance monotherapy with darunavir/ritonavir, 600/100 mg twice daily. VL was monitored monthly. ART was intensified in the case of VL > 50 copies/mL. Neonates received nevirapine prophylaxis for 14 days.

Results

Of 89 patients switching to darunavir/ritonavir monotherapy, 4 miscarried before 22 weeks’ gestation, 2 changed treatment for elevated liver enzymes without virological failure, and 83 were evaluable for the main outcome. Six had virological failure confirmed on a repeat sample (median VL = 193 copies/mL; range 78–644), including two before switching to monotherapy. In these six cases, ART was intensified with tenofovir disoproxil fumarate/emtricitabine. The success rate was 75/83, 90.4% (95% CI, 81.9%–95.7%) considering two patients with VL missing at delivery as failures, and 77/83, 92.8% (95% CI, 84.9%–97.3%) when considering them as successes since both had undetectable VL on darunavir/ritonavir throughout pregnancy. In ITT, the last available VL before delivery was <50 copies/mL in all of the patients. There was no case of perinatal HIV transmission.

Conclusions

Darunavir/ritonavir maintenance monotherapy required intensification in nearly 10% of cases. This limits its widespread use, thus other regimens should be evaluated in order to limit exposure to antiretrovirals, particularly NRTIs, during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsFemaleHumansInfant, NewbornPregnancyDarunavirRitonavirTreatment OutcomeViral Load

Substanzen

Anti-HIV AgentsDarunavirRitonavir

Autor:innen und Institutionen

  • Assistance Publique-Hôpitaux de Paris Hôpital Louis Mourier Service de Gynécologie-Obstétrique, F-92700 Colombes, France.
  • Université Paris Cité, F-75006 Paris, France.
  • INSERM, IAME, F-75018 Paris, France.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service Maladies infectieuses, F-75013 Paris, France.
  • INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
  • Laboratoire de microbiologie clinique, Groupe hospitalier Assistance Publique-Hôpitaux de Paris (APHP) Centre-Université Paris Cité, Hôpital Necker-Enfants Malades, F-75015 Paris, France.

ORCID-Profile: Laurent Mandelbrot, Pierre Frange, Gilles Peytavin, Véronique Avettand-Fenoel

Förderung

  • French national agency
  • Emerging infectious diseases

Zitieren

APA

Mandelbrot, L., Tubiana, R., Frange, P., Peytavin, G., Le Chenadec, J., Canestri, A., Morlat, P., Brunet-Cartier, C., Sibiude, J., Peretti, D., Chambrin, V., Chabrol, A., Bui, E., Simon-Toulza, C., Marchand, L., Paul, C., Delmas, S., Avettand-Fenoel, V., Warszawski, J., & Monogest study group (2023). Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad161

Vancouver

Mandelbrot L, Tubiana R, Frange P, Peytavin G, Le Chenadec J, Canestri A, et al. Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad161

BibTeX
@article{Mandelbrot2023,
  author = {Mandelbrot, Laurent and Tubiana, Roland and Frange, Pierre and Peytavin, Gilles and Le Chenadec, Jerome and Canestri, Ana and Morlat, Philippe and Brunet-Cartier, Cécile and Sibiude, Jeanne and Peretti, Delphine and Chambrin, Véronique and Chabrol, Amélie and Bui, Eida and Simon-Toulza, Caroline and Marchand, Lucie and Paul, Christelle and Delmas, Sandrine and Avettand-Fenoel, Véronique and Warszawski, Josiane and Monogest study group, Monogest study group},
  title = {Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad161}
}
Kostenlos starten →